News headlines about ACADIA Pharmaceuticals (NASDAQ:ACAD) have trended positive on Saturday, according to Accern. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ACADIA Pharmaceuticals earned a coverage optimism score of 0.26 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.8756506272476 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the headlines that may have impacted Accern Sentiment’s analysis:

Several equities research analysts recently weighed in on the company. ValuEngine raised ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 10th. Leerink Swann reaffirmed a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Monday, October 9th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 5th. Zacks Investment Research raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and set a $34.00 price target on the stock in a research note on Friday, August 11th. Finally, Cowen Inc reaffirmed an “outperform” rating and issued a $46.00 price target (up from $42.00) on shares of ACADIA Pharmaceuticals in a research note on Thursday, August 10th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $47.44.

Shares of ACADIA Pharmaceuticals (ACAD) opened at $28.00 on Friday. ACADIA Pharmaceuticals has a 12 month low of $24.31 and a 12 month high of $41.20.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.10. ACADIA Pharmaceuticals had a negative return on equity of 67.68% and a negative net margin of 320.71%. The business had revenue of $35.58 million for the quarter, compared to the consensus estimate of $32.03 million. During the same period in the previous year, the company posted ($0.61) earnings per share. The company’s revenue for the quarter was up 571.3% compared to the same quarter last year. research analysts anticipate that ACADIA Pharmaceuticals will post -2.42 EPS for the current fiscal year.

In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 37,500 shares of the business’s stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $40.91, for a total value of $1,534,125.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 22.25% of the company’s stock.

WARNING: This story was published by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Insider Buying and Selling by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.